Senior Partner, The Clymer Group

Jobless to start losing federal healthcare subsidy - 95.5 WBRU News

Jobless to start losing federal healthcare subsidy 95.5 WBRU News ... first of thousands of unemployed Rhode Islanders will lose a federal stimulus subsidy tomorrow that has helped them afford temporary health insurance. ... COBRA subsidy nearing its end

Jobs., Mortgages, Food Stamps -- Where is the President? - Huffington Post (blog)

New York Times (blog)

Jobs., Mortgages, Food Stamps -- Where is the President? Huffington Post (blog) Jacob Weisberg, over on Slate, cites pending health care legislation, the stimulus, and the reshaping of America's image abroad. The health care bill is ... Facing Bad Poll Numbers on Health Care, White House Asks "Who Do You Trust?" Debate on Creating Jobs, Without Raising Deficit Reader's view: Obama stimulus program is far from a bargain  - -

I Had Health Insurance From My Employer And Left My Job, What Happens? - Your Online Insurance News

TopNews United States

I Had Health Insurance From My Employer And Left My Job, What Happens? Your Online Insurance News Because of this, the government recently passed a stimulus plan that will cover 65 percent of the cost of COBRA health insurance plans for the first nine ... COBRA ending? Don't worry, you have options Insurance aid for jobless to expire Tuesday: Thousands in RI will begin to ... COBRA coverage subsidy ends soon for many  - -

Virdante Pharmaceuticals, Inc.: Series A $30M

Virdante Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on increasing potency of plasma-derived intravenous immune globulin for the treatment of inflammation and autoimmune disease, closed a $30M Series A financing. Participants include Thomas, McNerney & Partners, Osage Partners, Clarus Ventures, Venrock, MedImmune Ventures and Biogen Idec New Ventures.

Quinnova Pharmaceuticals, Inc.: Series B $17.4M

Quinnova Pharmaceuticals (Newtown, PA) a commercial-stage specialty biopharma company focused on dermatological drug reformulations and foam delivery systems, closed a $17.4M Series B financing. Participants include Safeguard Scientifics, Thomas, McNerney & Partners, H.I.G. Ventures.

Activaero, GmbH: Series A $15.9M

Activaero (Germany) a commercial-stage medical device company focused on patient-tailored controlled breathing and inhaled therapeutic delivery systems, closed a $15.9M Series A financing. Participants include BioMedPartners, VI Partners, Abalis Finance and Vesalius Biocapital.

3Q09 OnBioVC | Trend Analysis Now Available

Hot off the press! The 3Q09 OnBioVC | Trend Analysis study is now available for download [HERE]. Over $1,663M flowed into early-stage biopharma, diagnostic and device companies in the third quarter of 2009 and over $4,806M year-to-date! If you find the information in OnBioVC to be of value kindly forward on to colleagues who you [...]

September 2009 OnBioVC | Trend Analysis Now Available

Hot off the press! The September 2009 OnBioVC | Trend Analysis study is now available for download [HERE]. Over $465M flowed into early-stage biopharma, diagnostic and device companies in the ninth month of 2009 and over $4,806M year-to-date! If you find the information in OnBioVC to be of value kindly forward on to colleagues who [...]